Celluma wins the DigitRx Award for Product Innovation of the Year
This award recognises the most innovative products that are widely available on the market. Eligible products must have been launched into the UK market after 1 January 2018. The judges will look for genuine innovation or product advancement leading to treatment for new indications, quicker or easier treatments, better treatment outcomes and enhanced patient safety, all backed up by sound evidence. You are encouraged to keep your entry concise and clear; bullet points and the use of formatting options such as bold, underlines and italics are encouraged to ensure your entry is easy to digest for judges. A strict character limit of 1,700 (including spaces) is enforced for each question and you must not exceed this; however, your entry does not have to meet it. References are included in the character count, although you may supply a reference list as part of your supplementary materials if it exceeds the character count. There will be no voting process and the winner will be decided by the judging panel.
''We are extremely humbled to receive the DigitRx Award for Product Innovation of the Year from The Aesthetics Awards. It is our mission that advanced light therapy be more readily available, with greater efficacy, through innovative design and attention to scientific research. Our most profound gratitude to the Aesthetics Awards’ panel of judges who have recognized our efforts... and a big thank you to everyone who was part of the Celluma Team on Saturday night! Your well-wishes and company made this a heart-warming evening as well as a great professional achievement. Thank you for celebrating with us!'' the team of Celluma completes.
Celluma Light therapy has been shown to benefit tissue repair and regeneration, improve acne, skin tone, fine lines and wrinkles, as well as attenuate muscle and joint pain. Celluma is FDA-Cleared to treat full face wrinkles, acne, diminished local blood circulation, muscle and joint stiffness, muscle tissue tension, muscle and joint pain, muscle spasm, and arthritic pain. In 2016 Celluma gained CE Mark as a Class IIa medical device for all FDA-clearances as well as Dermal Wound Healing in the European Union and has more cleared indications–for-use than any single light therapy device on the market. Furthermore, clinical trials are underway using Celluma to treat peripheral neuropathy. It is expected that Celluma will be the first device of its kind to be FDA-Cleared for the treatment of this condition. This process, which applies light energy at specific intensities and wavelengths to accelerate biological functions, is often referred to as photobiostimulation. See attached paper: Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy.